Amino acid substitutions in NS5A region of GB virus C and response to interferon therapy

Journal of Medical Virology

Volumn 57, Issue 4, 1999, Pages 376-382

  Kato, Takanobu ^a   Mizokami, Masashi ^a   Orito, Etsuro ^a   Ohba, Ken Ichi ^a   Nakano, Tatsunori ^a   Kondo, Yutaka ^a   Tanaka, Yasuhito ^a   Ueda, Ryuzo ^a   Mukaide, Motokazu ^b   Yasuda, Kiyomi ^c   Iino, Shiro ^d  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b SRL INC   (Japan)

^c Kiyokawa Hospital   (Japan)

^d ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

GBV C; HGV; Interferon; ISDR; Single strand conformation polymorphism (SSCP)

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; BETA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS RNA;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONSENSUS SEQUENCE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS G VIRUS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NUCLEOTIDE SEQUENCE; SEQUENCE HOMOLOGY; SINGLE STRAND CONFORMATION POLYMORPHISM; TREATMENT OUTCOME; VIRUS GENOME; VIRUS LOAD;

GB VIRUS C/HEPATITIS G VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; LONCHOCARPUS GLAUCIFOLIUS; RNA VIRUSES;

EID: 0033020082     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1096-9071(199904)57:4<376::aid-jmv9>3.0.co;2-%23     Document Type: Article

References (34)

1. Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyama Y, Koike H, Kobayashi M, Koida I, Arase Y, Saito S, Suzuki Y, Murashima N, Ikeda K, Kumada H. 1997. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 25:745-749.
2. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, the Hepatitis Interventional Therapy Group. 1989. Treatment of chronic hepatitis C with recombinant interferon alfa: multicenter randomized, controlled trial. N Engl J Med 32:1501-1506.
3. Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato C. 1994. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J Gen Virol 75:1361-1369.
4. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C. 1995. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clinical Investigation 96:224-230.
5. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77-81.
6. Gale MJ Jr, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, Polyak SJ, Gretch DR, Katze MG. 1997. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230:217-227.
7. Hofgärtner WT, Polyak SJ, Sullivan DG, Carithers RL Jr, Gretch DR. 1997. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. J Med Virol 53:118-126.
8. Kato N, Lan KH, Ono-Nita SK, Shiratori Y, Omata M. 1997. Hepatitis C virus nonstructural region 5A protein is a potent transcriptional activator. J Virol 71:856-859.
9. Kato T, Mizokami M, Nakano T, Kondo Y, Ohba K, Onto E, Ueda R, Mukaide M, Gurtsevitch V, Syrtsev A, Ruzbakiev R, Abdurakhnamov M, Yamashita M, Hayami M. 1997. High prevalence of GB virus C/hepatitis G virus infection among the Jewish population in Uzbekistan. Virus Res 48:81-87.
10. Kato T, Mizokami M, Nakano T, Orito E, Ohba K, Kondo Y, Tanaka Y, Ueda R, Mukaide M, Fujita K, Yasuda K, Iino S. 1998. Heterogeneity in E2 region of GBV-C/hepatitis G virus and hepatitis C virus. J Med Virol 55:109-117.
11. Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, Ikeda T, Tozuka S, Izumi N, Marumo F, Sato C. 1997. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-β therapy. Hepatology 25:750-753.
12. Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC. 1993. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341: 1501-1504.
13. Lau JYN, Qian KP, Detmer J, Collins ML, Orito E, Kolberg JA, Urdea MS, Mizokami M, Davis GL. 1997. Effect of interferon-α and ribavirin therapy on serum GB virus C/hepatitis G virus (GBV-C) RNA levels in patients chronically infected with hepatitis C virus and GBV-C/HGV. J Inf Dis 176:421-426.
14. Leary TP, Muerhoff AS, Simons JN, Pilot-Matias TJ, Erker JC, Chalmers ML, Schlauder GG, Dawson GJ, Desai SM, Mushahwar IK. 1996. Sequence and genomic organization of GBV-C: a novel member of the Flaviviridae associated with human non-A - E hepatitis. J Med Virol 48:60-67.
15. Linnen J, Wages J, Zhang-Keck ZY, Fry KE, Krawczynski KZ, Alter H, Koonin E, Gallagher M, Alter M, Hadziyannis S, Karayiannis P, Fung K, Nakatsuji Y, Shih JWK, Young L, Piatak M Jr, Hoover C, Fernandez J, Chen S, Zoul JC, Morris T, Hyams KC, Ismay S, Lifson JD, Hess G, Foung SKH, Thomas H, Bradley D, Margolis H, Kim JP. 1996. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 271:505-508.
16. Ma J, Ptashne M. 1987. Deletion analysis of GAL4 defines two transcriptional activating segments. Cell 48:847-853.
17. Muerhoff AS, Simons JN, Leary TP, Erker JC, Chalmers ML, Pilot-Matias TJ, Dawson J, Desai SM, Mushahwar IK. 1996. Sequence heterogeneity within the 5′-terminal region of the hepatitis GB virus C genome and evidence for genotypes. J Hepatol 25:379-384.
18. Mukaide M, Mizokami M, Onto E, Ohba K, Nakano T, Ueda R, Hikiji K, Iino S, Shapiro S, Lahat N, Park YM, Kim BS, Oyunsuren T, Rezieg M, Al-Ahdal MN, Lau JYN. 1997. Three different GB virus C/hepatitis G virus genotypes: phylogenetic analysis and a genotyping assay based on restriction fragment length polymorphism. FEBS Letters 407:51-58.
19. Nagayama R, Miyake K, Okamoto H. 1997. Effect of interferon on GB virus C and hepatitis C virus in hepatitis patients with the co-infection. J Med Virol 51:156-160.
20. Ohba K, Mizokami M, Lau JYN, Orito E, Ikeo K, Gojobori T. 1996. Evolutionary relationship of hepatitis C, pesti-, flavi-, plantviruses, and newly discovered GB hepatitis agents. FEBS Letters 378:232-234.
21. Ohno T, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, Mukaide M, Williams R, Lau JYN. 1997. A new hepatitis C virus genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4, 5a, and 6a. J Clin Microbiol 35:201-207.
22. Okamato H, Okada S, Sugiyama Y, Tanaka T, Sugai Y, Akahane Y, Machida A, Mishiro S, Yoshizawa H, Miyakawa Y, Mayumi M. 1990. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from 5′-noncoding region. Jpn J Exp Med 60:215-222.
23. Orito E, Mizokami M, Nakano T, Terashima H, Nojiri O, Sakakibara K, Mizuno M, Ogino M, Nakamura M, Matsumoto Y, Miyata K, Lau JYN. 1994. Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-a therapy in Japanese patients with chronic hepatitis C. J Med Virol 44:410-414.
24. Orito E, Mizokami M, Yasuda K, Sugihara K, Nakamura M, Mukaide M, Ohba K, Nakano T, Kato T, Kondo Y, Kumada T, Ueda R, Iino S. 1997. Interferon-α therapy in patients dually infected with hepatitis C virus and GB virus C/hepatitis G virus: virological response of HGV and pretreatment HGV viremia level. J Hepatol 27:603-612.
25. Pickering JM, Thomas HC, Karayiannis P. 1997. Genetic diversity between hepatitis G virus isolates: analysis of nucleotide variation in the NS-3 and putative "core" peptide genes. J Gen Virol 78:53-60.
26. Sáiz JC, Ampurdanés S, Olemedo E, López-Labrador FX, Forns X, Guilera M, Tassies D, Costa J, Sánchez-Tapias JM, Jiménez de Anta MT, Rodés J. 1997. Hepatitis G virus infection in chronic hepatitis C: frequency, features and response to interferon therapy. J Hepatol 26:787-793.
27. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, Nakamura A, Asada M, Kuroda H, Tanaka N, Arakawa Y, Omata M. for the Tokyo-Chiba Hepatitis Research Group. 1997. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 113:558-566.
28. Simons JN, Leary TP, Dawson GJ, Pilot-Matias TJ, Muerhoff AS, Desai SM, Mushahwar IK. 1995. Isolation of novel virus-like sequences associated with human hepatitis. Nat Med 1:564-569.
29. Squadrito G, Leone F, Sartori M, Nalpas B, Berthelot P, Raimondo G, Pol S, Bréchot C. 1997. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology 113:567-572.
30. Takahashi K, Hijikata M, Hino K, Mishiro S. 1997. Entire polyprotein-ORF sequences of Japanese GBV-C isolates: implications for new genotypes. Hepatol Res 8:139-148.
31. Tanaka E, Alter HJ, Nakatsuji Y, Shih JWK, Kim JP, Matsumoto A, Kobayashi M, Kiyosawa K. 1996. Effect of hepatitis G virus infection on chronic hepatitis C. Ann Int Med 125:740-743.
32. Tanimoto A, Ide Y, Arima N, Sasaguri Y, Padmanabhan R. 1997. The amino terminal deletion mutants of hepatitis C virus nonstructural protein NS5A function as transcriptional activators in yeast. Biochem Biophy Res Comm 236:360-364.
33. Viazov S, Riffelmann M, Khoudyakov Y, Fields H, Varenholz C, Roggendorf M. 1997. Genetic heterogeneity of hepatitis G virus isolates from different parts of the world. J Gen Virol 79:577-581.
34. Zeuzem S, Lee JH, Roth WK. 1997. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 25:740-744.